All News
Anifrolumab shows long-term promise in patients with lupus
d
EurekAlert!
Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease.
Read Article
“Hey PRESTO!” – Early identification of psoriatic arthritis
Despite a wealth of treatment options, a number of notable unmet needs remain in PsA, most notably the significant diagnostic delay that many patients endure. We are all aware that those with psoriatic skin disease are the most at risk cohort for PsA. Identifying patients with psoriasis who have, or are at increased risk of PsA, appears to be the low hanging fruit that we just can’t fully seem to grasp.
Read Article
Long COVID and Rheumatic Disease
The COVID-19 pandemic has had a significant impact worldwide particularly among those who are immunocompromised. Numerous studies have highlighted the increased risk of acute SARS-CoV-2 infection among patients with rheumatic diseases (RD).
Read Article
Creaky Joints Presentations at ACR Convergence 2022
The patient advocacy organization CreakyJoints will present 13 scientific posters at this year's ACR Convergence 2022 and 8 posters as part of the patient perspectives track. Below is a sampling of these scientific posters.
Read Article
Progression from non-radiographic to radiographic AxSpA is not the norm
● 16% progress over 5 years, 10-25% over 10 years
● Syndesmophytes in 20% over 4 years
● Male, MRI+ at baseline, response to NSAIDs are predictors of progression
Jose U Scher, Review @RheumNow #ACR22 https://t.co/FatodINTfn
Dr. Antoni Chan synovialjoints ( View Tweet)
ASAS-EULAR Rec for AxSpA 2022
◦ NSAIDs are first line
◦ b/tsDMARDs when ASDAS >2.1
◦ Uveitis/IBD ➤TNFi
◦ Psoriasis ➤IL-17i
◦ Review Dx if Rx failure
◦ Switch if active disease confirmed
◦ Taper bDMARDs if sustained remission
Jose Scher #ReviewCourse @RheumNow #ACR22 https://t.co/8fGwlZWBDS
Dr. Antoni Chan synovialjoints ( View Tweet)
IL-17i Ixekizumab (IXE) continuation superior to withdrawal in preventing relapse in PsA
● Withdrawal resulted in relapse at median 22 wk
● Continuation vs withdrawal 38% vs 85% relapse
● 96% regained control after reinstating IXE
Jose Scher #ReviewCourse @RheumNow #ACR22 https://t.co/TgIRe14Vud
Dr. Antoni Chan synovialjoints ( View Tweet)
Think of paraneoplastic presentations for
◦ RS3PE 16-30% malignancy
◦ PPP 12% pancreatic ca
◦ HPOA 1% lung ca
◦ EF 10% haem ca
◦ LCV 4% malignancy
◦ Erythromelalgia 10% haem ca
Screen for malignancies esp if treatment resistant
Capelli L #ReviewCourse @RheumNow #ACR22 https://t.co/tEaf7wCAcj
Dr. Antoni Chan synovialjoints ( View Tweet)
Not all dry eyes and mouth is due to Sjogren’s syndrome (SS). Think of mimics including diabetes, HCV, HIV, sarcoidosis.
Equally, not all parotid enlargement is due to SS. Think of mimics including IgG4, sialodenosis #ReviewCourse @RheumNow #ACR22 https://t.co/zPwRRtdGjT
Dr. Antoni Chan synovialjoints ( View Tweet)
The calm before the #ACR22 deluge! Let’s go learn! Follow https://t.co/nDsfMGdiq8 for our conference coverage! @RheumNow #rheumpix @doctorRBC @DrPetryna @KDAO2011 @RichardPAConway @ericdeinmd @EBRheum @gensler_MD @Janetbirdope and more! https://t.co/nTX48dWA4g
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR22 meeting in Philadelphia.
https://t.co/WGUYSUmFYz https://t.co/yGSROf5XU6
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate (MTX) works in early PsA. Confirms what we see in clinical practice
◦ Mean disease duration 0.6y
◦ bDMARD naive
◦ MTX monotherapy
➢ ACR20 50.7%
➢ ACR50 30.6%
➢ MDA 22.9%
Good to know, our trusted friend MTX works
Jose Scher #ReviewCourse @RheumNow #ACR22 https://t.co/ECyM4qtliG
Dr. Antoni Chan synovialjoints ( View Tweet)
Treatment algorithm for Raynaud’s secondary to systemic sclerosis
CCB ➤ PDE5i ➤ ARB ➤ Prostanoid ➤ Switch CCB
John Pauling #ReviewCourse @RheumNow #ACR22 https://t.co/UXFpKdRuC5
Dr. Antoni Chan synovialjoints ( View Tweet)
Low dose IL-2 works in Primary Sjogrens Syndr (pSS)? RCT 60 pSS pts rx w/ PBO vs LD-IL-2; latter lower ESSDAI @wk 24 (67% vs 27%; P=.004) & less Sxs (dryness,fatigue) @wk12 and expansion of TREGs & CD24highCD27+ B cells. https://t.co/39U6WX7ceM https://t.co/i56XDSvGXs
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Olga Petryna is back for her 8th year as a RheumNow reporter. Follow her @DrPetryna for real-time #ACR22 coverage. https://t.co/zwCt46uqQj
Dr. John Cush RheumNow ( View Tweet)
Introducing RheumNow #ACR22 reporter, Dr. Catherine Sims! She'll will be joining us and reporting on SpA and reproductive health. Follow @DrCassySims for real-time ACR coverage this weekend! https://t.co/LU39uYs6WM
Dr. John Cush RheumNow ( View Tweet)
Hear what KOLs are saying about #ACR22. We are featuring Drs: Michele Petri, Peter Nash, Artie Kavanaugh, Jack Cush. Follow us on Twitter and head to https://t.co/V10S4oE43V for real-time coverage. https://t.co/Qj8tSwsEiJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Which one to use for prevention and which for treatment? Drugs covered by #Medicare based on indication #osteoporosis #acr22 #acrreview @RheumNow https://t.co/KE5F6Sn3wg
TheDaoIndex KDAO2011 ( View Tweet)
What's the role of MRI in #osteoarthritis?
#ACR22 @RheumNow #acrreview https://t.co/uZEzUSLo88
sheila RHEUMarampa ( View Tweet)
When referring to radiographs in #osteoarthritis, it can be better described as early, advanced or end-stage as it only shows the extent of joint damage accrued over time, not telling us much on the severity of disease - Dr. Scanzello
#ACR22 @RheumNow https://t.co/m7Vdmu6KM6
sheila RHEUMarampa ( View Tweet)